Gilead's Sofosbuvir Succeeds in Phase 3 Trials

Biotech company Gilead Sciences (NASDAQ: GILD  ) reported in a press release Monday that two phase 3 studies evaluating its hepatitis C therapy sofosbuvir both hit their primary endpoints. Gilead will use the data learned from the trials as part of its regulatory filing for sofosbuvir.

Gilead's hope is to file for sofosbuvir's approval with the FDA later this year. If approved, the drug -- which Gilead acquired as part of last year's $11 billion acquisition of Pharmasset -- would become the first purely oral treatment for hepatitis C. Analysts have pegged the disease's market to climb substantially in coming years, potentially to $20 billion.

Dr. Norbert Bischofberger, Gilead's chief science officer and executive vice president of research and development, explained the results in the release: "These data support the favorable clinical profile of sofosbuvir as the backbone of a potent, safe, and well-tolerated treatment regimen that is effective across a broad range of HCV patient genotypes. ...The sofosbuvir regimens in these trials allowed us to shorten the duration of effective hepatitis C therapy to just 12 weeks for treatment-naive patients with genotypes 1 through 6."

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2235014, ~/Articles/ArticleHandler.aspx, 4/17/2014 12:21:24 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

TREND TRACKER: Get Rich When the Web Goes Dark

It's time to say "goodbye" to your Internet! One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism… The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." Big money is already on the move. Don't be too late to the party – find out the 1 stock to own when the Web goes dark.